Managing the underestimated risk of statin-associated myopathy.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  International Journal of Cardiology

• Publication date

  2012-09-06

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.ijcard.2011.07.048PMID 21813193
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Attainment of optional low-density lipoprotein cholesterol goal of less than 70 mg/dl and impact on prognosis of very high risk stable coronary patients: a 3-year follow-up

  2011cited by this paper
• Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12 064 survivors of myocardial infarction: a double-blind randomised trial

  2010cited by this paper
• Approach to the patient who is intolerant of statin therapy.

  2010cited by this paper
• Incidence of perioperative myocardial infarction and of 2-year mortality in 577 elderly patients undergoing noncardiac vascular surgery treated with and without statins.

  2010cited by this paper
• Statin‐Associated Muscle‐Related Adverse Effects: A Case Series of 354 Patients

  2010cited by this paper
• Tolerability of red yeast rice (2,400 mg twice daily) versus pravastatin (20 mg twice daily) in patients with previous statin intolerance.

  2010cited by this paper
• Lipid-lowering efficacy of red yeast rice in a population intolerant to statins.

  2010cited by this paper
• Centralized Pan-European survey on the under-treatment of hypercholesterolaemia (CEPHEUS): overall findings from eight countries

  2010cited by this paper
• The genetics of statin-induced myopathy.

  2010cited by this paper
• Do statins cause myopathy by lowering vitamin E levels?

  2010cited by this paper
• Ethics in the authorship and publishing of scientific articles

  2010cited by this paper
• Statins and noncardiac surgery: Current evidence and practical considerations

  2009cited by this paper
• Managing statin myopathy.

  2009influential reference
• Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH)

  2009cited by this paper
• Statins and coronary artery bypass graft surgery: preoperative and postoperative efficacy and safety

  2009cited by this paper
• Red Yeast Rice for Dyslipidemia in Statin-Intolerant Patients

  2009cited by this paper
• Once-a-week rosuvastatin (2.5 to 20 mg) in patients with a previous statin intolerance.

  2009cited by this paper
• Does Simvastatin Cause More Myotoxicity Compared with Other Statins?

  2009cited by this paper
• Association between statin-associated myopathy and skeletal muscle damage

  2009cited by this paper
• Rhabdomyolysis a result of azithromycin and statins: an unrecognized interaction.

  2009cited by this paper
• Molecular basis of statin-associated myopathy.

  2009cited by this paper
• Should high creatine kinase discourage the initiation or continuance of statins for the treatment of hypercholesterolemia?

  2009cited by this paper
• The SLCO1B1*5 genetic variant is associated with statin-induced side effects.

  2009cited by this paper
• Colesevelam hydrochloride: usefulness of a specifically engineered bile acid sequestrant for lowering LDL-cholesterol

  2009cited by this paper
• How do you treat patients with myalgia who take statins?

  2009cited by this paper
• Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries.

  2009cited by this paper
• Toward "pain-free" statin prescribing: clinical algorithm for diagnosis and management of myalgia.

  2008cited by this paper
• SLCO1B1 variants and statin-induced myopathy--a genomewide study.

  2008cited by this paper
• Effects of fluvastatin extended-release (80 mg) alone and in combination with ezetimibe (10 mg) on low-density lipoprotein cholesterol and inflammatory parameters in patients with primary hypercholesterolemia: a 12-week, multicenter, randomized, open-label, parallel-group study.

  2008cited by this paper
• Effects of ubiquinone (coenzyme Q10) on myopathy in statin users

  2008cited by this paper
• Recommendations for the use of LDL apheresis.

  2008cited by this paper
• Efficacy of rosuvastatin (5 mg and 10 mg) twice a week in patients intolerant to daily statins.

  2008cited by this paper
• Efficacy and tolerability of fluvastatin XL 80 mg alone, ezetimibe alone, and the combination of fluvastatin XL 80 mg with ezetimibe in patients with a history of muscle-related side effects with other statins.

  2008cited by this paper
• Ezetimibe-related myopathy: A systematic review.

  2008cited by this paper
• Review of side-effect profile of combination ezetimibe and statin therapy in randomized clinical trials.

  2008cited by this paper
• Effectiveness and Tolerability of Every-Other-Day Rosuvastatin Dosing in Patients with Prior Statin Intolerance

  2008cited by this paper
• Effectiveness of ezetimibe alone or in combination with twice a week Atorvastatin (10 mg) for statin intolerant high-risk patients.

  2008cited by this paper
• Myopathies associated with red yeast rice and liquorice: spontaneous reports from the Italian Surveillance System of Natural Health Products.

  2008cited by this paper
• Effect of ezetimibe in patients who cannot tolerate statins or cannot get to the low density lipoprotein cholesterol target despite taking a statin

  2007cited by this paper
• Creatine kinase monitoring in sport medicine.

  2007cited by this paper
• Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins

  2007cited by this paper
• Effect of coenzyme q10 on myopathic symptoms in patients treated with statins.

  2007cited by this paper
• Does statin therapy initiation increase the risk for myopathy? An observational study of 32,225 diabetic and nondiabetic patients.

  2007cited by this paper
• The role of coenzyme Q10 in statin-associated myopathy: a systematic review.

  2007cited by this paper
• Effect of coenzyme Q(10) supplementation on simvastatin-induced myalgia.

  2007cited by this paper
• Tolerability of statins is not linked to CYP450 polymorphisms, but reduced CYP2D6 metabolism improves cholesteraemic response to simvastatin and fluvastatin.

  2007cited by this paper
• Colesevelam hydrochloride-ezetimibe combination lipid-lowering therapy in patients with diabetes or metabolic syndrome and a history of statin intolerance.

  2007cited by this paper
• The broad spectrum of statin myopathy: from myalgia to rhabdomyolysis

  2007influential reference
• Efficacy of Monascus purpureus Went rice on lowering lipid ratios in hypercholesterolemic patients

  2007cited by this paper
• Effects of once weekly rosuvastatin among patients with a prior statin intolerance.

  2007cited by this paper
• Statin-related adverse events: a meta-analysis.

  2006cited by this paper
• Ezetimibe-associated myopathy in monotherapy and in combination with a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor.

  2006cited by this paper
• Risks Associated With Statin Therapy: A Systematic Overview of Randomized Clinical Trials

  2006cited by this paper
• Statin safety and drug interactions: clinical implications.

  2006cited by this paper
• An assessment of statin safety by muscle experts.

  2006cited by this paper
• Clinical perspectives of statin-induced rhabdomyolysis.

  2006cited by this paper
• Statin-induced apoptosis and skeletal myopathy.

  2006cited by this paper
• Rosuvastatin 5 and 10 mg/d: a pilot study of the effects in hypercholesterolemic adults unable to tolerate other statins and reach LDL cholesterol goals with nonstatin lipid-lowering therapies.

  2006cited by this paper
• Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin.

  2005cited by this paper
• Intensive lipid lowering with atorvastatin in patients with stable coronary disease.

  2005cited by this paper
• High‐dose statins and skeletal muscle metabolism in humans: A randomized, controlled trial

  2005cited by this paper
• Statin-Induced Muscle Necrosis in the Rat: Distribution, Development, and Fibre Selectivity

  2005cited by this paper
• Molecular clues into the pathogenesis of statin‐mediated muscle toxicity

  2005cited by this paper
• Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins.

  2005cited by this paper
• Implications of statin adverse effects in the elderly

  2005cited by this paper
• Results of the National Cholesterol Education (NCEP) Program Evaluation ProjecT Utilizing Novel E-Technology (NEPTUNE) II survey and implications for treatment under the recent NCEP Writing Group recommendations.

  2005cited by this paper
• Mild to Moderate Muscular Symptoms with High-Dosage Statin Therapy in Hyperlipidemic Patients —The PRIMO Study

  2005influential reference
• Professional athletes suffering from familial hypercholesterolaemia rarely tolerate statin treatment because of muscular problems.

  2004cited by this paper
• Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs.

  2004cited by this paper
• Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines

  2004cited by this paper
• Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines

  2004cited by this paper
• Cerivastatin and reports of fatal rhabdomyolysis.

  2002cited by this paper
• MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial.

  2002cited by this paper
• Etiology and Frequency of Rhabdomyolysis

  2002cited by this paper
• Statin-Associated Myopathy with Normal Creatine Kinase Levels

  2002cited by this paper
• ACC/AHA/NHLBI clinical advisory on the use and safety of statins.

  2002influential reference
• MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Commentary

  2002cited by this paper
• ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins.

  2002cited by this paper
• Two different types of exercise-induced muscle pain without myopathy and CK-elevation during HMG-Co-enzyme-A-reductase inhibitor treatment.

  1999cited by this paper
• 3-Hydroxy-3-methylglutaryl coenzyme a reductase and isoprenylation inhibitors induce apoptosis of vascular smooth muscle cells in culture.

  1998cited by this paper
• Inhibition of cholesterol synthesis by squalene synthase inhibitors does not induce myotoxicity in vitro.

  1997cited by this paper
• Myopathy associated with lipid lowering therapy in patients with previously undiagnosed or undertreated hypothyroidism.

  1996cited by this paper
• Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group.

  1995cited by this paper
• Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia

  1995cited by this paper
• Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)

  1994cited by this paper

• Guideline for Chronic Coronary Syndrome - 2025.

  2025cites this paper
• The Multifaceted Anti-Atherosclerotic Properties of Herbal Flavonoids: A Comprehensive Review.

  2024cites this paper
• Executive summary of the Hellenic Atherosclerosis Society guidelines for the diagnosis and treatment of dyslipidemias - 2023.

  2024cites this paper
• The Link between miRNAs and PCKS9 in Atherosclerosis.

  2023cites this paper
• Achievement of Low-Density Lipoprotein Cholesterol Targets in Cardiac Rehabilitation: Impact of the 2019 ESC/EAS Dyslipidaemia Guidelines

  2022cites this paper
• Frequency of functional exonic single-nucleotide polymorphisms and haplotype distribution in the SLCO1B1 gene across genetic ancestry groups in the Qatari population

  2022cites this paper
• Cordycepin as a Metabolite with Pharmacological Potential: A Review.

  2022cites this paper
• The Possible Role of Nanocurcumin in Rat Model of Statin Induced Myopathy: Histological and Immune Histochemical Study

  2022cites this paper
• Muscle pain and muscle weakness in COVID19 patients: Cross-talk with statins – Preliminary results

  2022cites this paper
• Drug handling by elderly kidney: a prospective review to senile kidney physiology

  2022cites this paper
• Role of Drug–Gene Interactions and Pharmacogenetics in Simvastatin-Associated Pulmonary Toxicity

  2021cites this paper
• Therapeutic advancement of simvastatin-loaded solid lipid nanoparticles (SV-SLNs) in treatment of hyperlipidemia and attenuating hepatotoxicity, myopathy and apoptosis: Comprehensive study.

  2021cites this paper
• Statin-Associated Myopathy: Emphasis on Mechanisms and Targeted Therapy

  2021cites this paper
• Protective Effects of Statin Therapy in Cirrhosis Are Limited by a Common SLCO1B1 Transporter Variant

  2021cites this paper
• A systematic review and meta-analysis of genotype-based and individualized data analysis of SLCO1B1 gene and statin-induced myopathy

  2021cites this paper
• Traitement des dyslipidémies : moyens pharmacologiques, indications et recommandations thérapeutiques

  2020cites this paper
• Statins and muscle pain

  2020cites this paper
• Risk Factors for SAMS

  2020cites this paper
• Genetic Variations and Frequencies of the Two Functional Single Nucleotide Polymorphisms of SLCO1B1 in the Thai Population

  2020cites this paper
• Clinical features related to statin‐associated muscle symptoms

  2019cites this paper
• Protection effect of Acalypha indica L. extract versus combination of Acalypha indica L.- gemfibrosil against fatty renal induced high-fructose and fat diets in rats

  2019cites this paper
• [The problem of safety of lipid-lowering therapy].

  2019cites this paper
• Economic evaluations of a pharmacogenomics test for Statin-induced myopathy in secondary cardiovascular prevention

  2019influential citation
• A Review of PCSK9 Inhibitors and their effects on cardiovascular disease.

  2019cites this paper
• Effect of Simvastatin on the Skeletal Muscles of Senile Male Albino Rats and Possible Protective Role of L- Carnitine. A Histological Study

  2019cites this paper
• A novel investigation of statins myotoxic mechanism: effect of atorvastatin on respiratory muscles in hypoxic environment.

  2019cites this paper
• The effects of statins with a high hepatoselectivity rank on the extra-hepatic tissues; new functions for statins.

  2019cites this paper
• Statins with different lipophilic indices exert distinct effects on skeletal, cardiac and vascular smooth muscle.

  2019cites this paper
• A practical algorithm for the management of patients with statin-associated muscle symptoms.

  2019cites this paper
• Value of a Hypothetical Pharmacogenomic Test for the Diagnosis of Statin-Induced Myopathy in Patients at High Cardiovascular Risk

  2018cites this paper
• MUSCLE ADVERSE EVENTS AMONG USERS OF SIMVASTATIN IN PRIMARY HEALTH CARE: COLLABORATIVE DRUG THERAPY MANAGEMENT

  2018cites this paper
• A Discrete Event Simulation Model to Assess the Economic Value of a Hypothetical Pharmacogenomics Test for Statin-Induced Myopathy in Patients Initiating a Statin in Secondary Cardiovascular Prevention

  2018cites this paper
• The effect of statin treatment on circulating coenzyme Q10 concentrations: an updated meta-analysis of randomized controlled trials

  2018cites this paper
• [Is it possible to improve long-term compliance of patients to statin therapy?]

  2018cites this paper
• Efficacy and Safety of Alternate-Day Versus Daily Dosing of Statins: a Systematic Review and Meta-Analysis

  2017cites this paper
• Xanthohumol Suppresses Mylip/Idol Gene Expression and Modulates LDLR Abundance and Activity in HepG2 Cells.

  2017cites this paper
• THE EFFECT OF ORALLY INGESTED ATORVASTATIN ON THE MASSETER MUSCLE OF WHITE ALBINO RATS (HISTOLOGICAL AND IMMUNOHISTOCHEMICAL STUDIES)

  2017cites this paper
• Rosuvastatin safety: An experimental study of myotoxic effects and mitochondrial alterations in rats.

  2017cites this paper
• Histopathologic and Biochemical Evidence for Mitochondrial Disease Among 279 Patients with Severe Statin Myopathy

  2017cites this paper
• Assessment of Atorvastatin Effect on Body Weight and Blood Glucose Levels Among Diabetic and Non-Diabetic Patients

  2017cites this paper
• [Statin associated myopathy in clinical practice. Results of DAMA study].

  2017cites this paper
• Therapeutic properties of Pleurotus species (oyster mushrooms) for atherosclerosis: A review

  2017cites this paper
• Miopatía asociada al uso de estatinas en la práctica clínica. Resultados del estudio DAMA

  2017cites this paper
• Statin associated myopathy in clinical practice. Results of DAMA study

  2017cites this paper
• Structural Changes in the Skeletal Muscle Fiber of Adult Male AlbinoRat Following Atorvastatin Treatment; the Possible Mechanisms ofAtorvastatin Induced Myotoxicity

  2017cites this paper
• Muscle- and skeletal-related side-effects of statins: tip of the iceberg?

  2016cites this paper
• PCSK9 inhibition as an emerging lipid lowering therapy: Unanswered questions.

  2016cites this paper
• Statin-Associated Muscle Adverse Events: Update for clinicians.

  2016cites this paper
• Tanshinone IIA Modulates Low Density Lipoprotein Uptake via Down-Regulation of PCSK9 Gene Expression in HepG2 Cells

  2016cites this paper
• Vitamin D Deficiency in Muscle

  2016cites this paper
• Reduction of cholesterol and markers of oxidation in serum of hypercholestrolemic patients treated with lycosome formulation of simvastatin

  2016cites this paper
• Simvastatin monotherapy as a potential option for statin‐associated muscle symptoms: a case report

  2016cites this paper
• Human sterol 14α-demethylase as a target for anticancer chemotherapy: towards structure-aided drug design1

  2016cites this paper
• Comparative Study of the Myopathic Effects of Atorvastatin and Rosuvastatin in Rats

  2016cites this paper
• Safe use of statins: focus on muscle toxicity

  2016cites this paper
• Elucidation of the mechanism of atorvastatin-induced myopathy in a rat model.

  2016cites this paper
• Severity of statin-induced adverse effects on muscle and associated conditions: data from the DAMA study

  2016cites this paper
• Economic Evaluation of a Pharmacogenomics Test for Statin-Induced Myopathy in Cardiovascular High-Risk Patients Initiating a Statin

  2016cites this paper
• Hypothyroidism Is a Risk Factor for New-Onset Diabetes: A Cohort Study

  2015cites this paper
• Analysis of vitamin D levels in patients with and without statin-associated myalgia - a systematic review and meta-analysis of 7 studies with 2420 patients.

  2015influential citation
• Risk identification and possible countermeasures for muscle adverse effects during statin therapy.

  2015cites this paper
• Management of Statin Intolerance (Si) in Patients at High Risk for Cardiovascular (Cv) Events: Results of a Canadian Study.

  2015cites this paper
• Drug management in the elderly adult with chronic kidney disease: a review for the primary care physician.

  2015cites this paper
• PCSK9 inhibition to reduce cardiovascular disease risk: recent findings from the biology of PCSK9

  2015cites this paper
• Adenosine triphosphate citrate lyase: Emerging target in the treatment of dyslipidemia.

  2015cites this paper
• The impact of physical activity on statin-associated skeletal muscle myopathy

  2015cites this paper
• Statin-Induced Musculoskeletal Problems: Disconcerting Reports and Data

  2015cites this paper
• Genetic association study of plasma creatine kinase levels in the Montreal Heart Institute Hospital Cohort

  2015cites this paper
• Management of dyslipidaemia in statin-intolerant patients in light of AHA and NPA guidelines of 2013–2014

  2015cites this paper
• 홍국발효가 백태와 서리태의 생리활성 성분에 미치는 영향

  2015cites this paper
• Hypothyroidism Is a Risk Factor for New-Onset Diabetes Mellitus: A Cohort Study

  2015cites this paper
• Abnormal splicing of NEDD4 in myotonic dystrophy type 2: possible link to statin adverse reactions.

  2014cites this paper
• "ESTATINAS, MIOPATIA E EXERCÍCIO FÍSICO"

  2014cites this paper
• Is myopathy the Achilles' heel of statins?: differences between the new cholesterol treatment guidelines and everyday clinical practice.

  2014cites this paper
• An Update on the Benefits and Risks of Rosuvastatin Therapy

  2014cites this paper
• Недиагностированный гипотиреоз - фактор риска возникновения рабдомиолиза при терапии статинами

  2014cites this paper
• Genetic association study of plasma creatine kinase levels in the Montreal Heart

  2014cites this paper
• A dangerous mixture

  2014cites this paper
• Giant Cell Arteritis and Polymyalgia Rheumatica After Reexposure to a Statin: A Case Report

  2014cites this paper
• Combination therapy in dyslipidemia: where are we now?

  2014cites this paper
• Translational insight into statin-induced muscle toxicity: from cell culture to clinical studies.

  2014cites this paper
• Alirocumab: PCSK9 inhibitor for LDL cholesterol reduction

  2014cites this paper
• [Adherence to statin treatment and associated factors in female users from the Unified Health System (SUS)].

  2014cites this paper
• Large pore mesoporous silica induced weight loss in obese mice.

  2014cites this paper
• Genetically Guided Statin Therapy on Statin Perceptions, Adherence, and Cholesterol Lowering: A Pilot Implementation Study in Primary Care Patients

  2014cites this paper
• Statin-Induced Musculoskeletal Problems : Disconcerting Reports and Data

  2014cites this paper
• Pharmacoepidemiologic studies: An interrupted-time series analysis on drug utilization and evaluation of beneficial or adverse drug effects

  2013cites this paper
• Subclinical hypothyroidism and vascular risk: An update

  2013cites this paper
• Effects of Lipid-Lowering Drugs on Irisin in Human Subjects In Vivo and in Human Skeletal Muscle Cells Ex Vivo

  2013cites this paper
• Muscular effects of statins in the elderly female: a review

  2013cites this paper
• Intermittent Nondaily Dosing Strategies in Patients with Previous Statin-Induced Myopathy

  2013cites this paper
• A Change of Statin Leading to Severe Rhabdomyolysis and Acute KidneyInjury

  2013cites this paper
• Does combination therapy with statins and fibrates prevent cardiovascular disease in diabetic patients with atherogenic mixed dyslipidemia?

  2013cites this paper
• Chapter 3 – The respiratory muscles

  2013cites this paper
• Statiny a myopatie

  2013influential citation
• Hypolipidemic and antiatherosclerotic potential of Pleurotus ostreatus, cultived by submerged fermentation in the high-fat diet fed rats

  2013cites this paper
• Hypothyroidism as a risk factor for statin intolerance.

  2013cites this paper
• Drug Use Evaluation of Statins Focused on Drug-Drug Interactions

  2013cites this paper
• Drug Information Rounds Request What evidence exists regarding the safety and efficacy of intermittent nondaily statin dosing strategies in patients who have experienced previous statin-induced myopathy ?

  2013cites this paper
• Characterization of statin treatment in basic healthcare unit

  2013cites this paper